Notable Mergers and Acquisitions of the Day 7/2: JNJ/ELN, FCSX/IAAC, LSTR
More News related to ELN
- El Nino Closes $1.5 Million Non-Brokered Private Placement; Update on the Kasala Copper Project in the DRC
- The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments
- Elan to Present at Lazard Capital Markets 6th Annual Healthcare Conference
- Elan Corporation Plc Announces Expiration of Tender Offer for 73/4% Senior Fixed Rate Notes Due 2011
- UBS Downgrades Elan (ELN) to Neutral
More News related to EXC
- Exelon Power Seeks to Permanently Retire Four Units in Southeastern Pennsylvania
- Exelon Generation (EXC) Tells PJM Interconnection of Intention to Retire Units 1 and 2 at Cromby and Eddystone Generating Stations
- Deutsche Bank Starts Coverage on Utilities Stocks: CMS, AEP, EIX, ITC, PSEG at Buy
- LED Lighting Brightens Holiday Season with Energy Savings
- PECO: Natural gas rate down 17% compared with last winter
More News related to FCSX
- FCStone Group (FCSX) Key Monthly Performance Metrics for June 2009
- Morning Movers 7/9: RIGL, PURE, SOMX, YRCW, AXL, NTWK Higher; NVGN, ELX, VRGY, EXAC, SIMO Lower
- FCStone (FCSX) Tops Q3 Earnings Views
- Trading Radar for 7/9: Chevron (CVX), Shaw Group (SGR), 3Com (COMS), Chattem (CHTT), FCStone (FCSX) Report; Initial Claims, Wholesale Inventories Due
- Notable Mergers and Acquisitions of the Day 7/2: JNJ/ELN, FCSX/IAAC, LSTR
More News related to Special Reports
- Spectranetics (SPNC) Receives U.S. FDA OK for VisiSheath Dilator Sheath Device
- Endo Pharmaceuticals (ENDP) Receives Complete Response Letter From FDA Regarding AVEED
- Simcere Pharma (SCR) Rabies Vaccine to be Investigated by China's SFDA
- Cubist Pharmaceuticals (CBST) Temporarily Suspends Enrollment In One Trial After More Deaths
- AstraZeneca (AZN) and Targacept (TRGT) To Collaborate to Develop and Commercialize TC-5214 MDD Drug
StreetInsider.com Notable Mergers and Acquisitions of the Day:
- Johnson & Johnson (NYSE: JNJ) and Elan Corporation plc (NYSE: ELN) announced a definitive agreement whereby Johnson & Johnson will acquire substantially all of the assets and rights of Elan related to its Alzheimer's Immunotherapy Program (AIP Program), through a newly formed company. In addition, Johnson & Johnson, through its affiliate, will invest $1 billion in Elan in exchange for newly issued American Depositary Receipts (ADRs) of Elan which will represent 18.4% of Elan's outstanding ordinary shares.
In consideration for the transfer of these rights and assets, Elan will receive a 49.9% equity interest in the newly formed Johnson & Johnson company that will acquire the AIP Program. Elan will be entitled to a 49.9% share of the profits and certain royalty payments upon the commercialization of products under the collaboration with Wyeth.
- International Assets Holding Corporation (Nasdaq: IAAC) and FCStone Group, Inc. (Nasdaq: FCSX) announced that they have signed a to merge in a share swap that creates a combined company with a market capitalization of approximately $260 million.
- Exelon Corporation (NYSE: EXC) increase in its offer to acquire all of the outstanding NRG (NYSE: NRG) common stock in an all-stock transaction with a fixed exchange ratio of 0.545 of a share of Exelon common stock for each NRG share, a 12.4% increase over the initial exchange offer of 0.485. Exelon's increased offer represents value of over $3 billion to NRG shareholders.
Based on yesterday's close the deal is worth $28.10 per share to NRG shareholders, versus yesterday's NRG close of $26.05.
- Hewitt Associates (NYSE: HEW) has acquired the remaining interest in BodeHewitt AG & Co KG, a German pensions and benefits consulting specialist, from Bayerische Hypo- und Vereinsbank AG (HVB).
- Landstar System (Nasdaq: LSTR) announced the acquisition of two supply chain transportation integration companies, Premier Logistics, Inc. (Premier) and A3 Integration LLC.
- Exelon Corporation (NYSE: EXC) increase in its offer to acquire all of the outstanding NRG (NYSE: NRG) common stock in an all-stock transaction with a fixed exchange ratio of 0.545 of a share of Exelon common stock for each NRG share, a 12.4% increase over the initial exchange offer of 0.485. Exelon's increased offer represents value of over $3 billion to NRG shareholders.
Related Categories
Special ReportsStocks Mentioned
+0.02
-0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
